Explore our materials

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #4 - Determination of drug resistance of hepatitis C virus to NS5A protein inhibitors as a new approach to personalized medicine - Elena Gasich, Belarus

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #3 - Evidence of experience in Community-based HCV Treatment among HIV/HCV Co-infected PWIDs in Ukraine - Zahedul Islam, Alliance Public Health, Ukraine

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #2 - A pilot study of the acceptability and feasibility of HCV self-testing among key populations in Georgia - Sonjelle Shilton, FIND, Switzerland

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract # 1 - Characteristics of women diagnosed with HIV in the WHO European Region and predictors of late diagnosis - Otilia Mårdh, ECDC, Sweden

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Debate: Do Integrase Inhibitors and/or TAF Lead to Weight Gain? - Dr. Jürgen Rockstroh Con Standpoint -

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Long-Acting Therapies: Which Patients Will Benefit Most? - Sharon Walmsley

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

The Acute HCV Epidemic in MSM: What Have We Learned Thus Far? - Christoph Boesecke

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Managing Highly Treatment-Experienced Patients: What are the New Drug Options - Prof. Anca Streinu Cercel

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Management of Viral Hepatitis During Pregnancy - Dr. Yvonne Gilleece

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

ART in Women: Which Drugs are Safe and What are the Challenges? - Dr. Annette Haberl

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

PrEP Implementation in the CEE Region - Prof. Milosz Parczewski